Cargando…

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is strongly associated with cardiovascular disease in the general population. Both conditions seem more frequent in patients with inflammatory bowel disease (IBD). We aimed to assess the effect of NAFLD and liver fibrosis on intermediate–high card...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kablawi, Dana, Aljohani, Faisal, Palumbo, Chiara Saroli, Restellini, Sophie, Bitton, Alain, Wild, Gary, Afif, Waqqas, Lakatos, Peter L, Bessissow, Talat, Sebastiani, Giada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951742/ https://www.ncbi.nlm.nih.gov/pubmed/36846097 http://dx.doi.org/10.1093/crocol/otad004

Ejemplares similares

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

A34 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease
por: Chao, Che-Yung, et al.
Publicado: (2019)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article
por: Chao, Che-Yung, et al.
Publicado: (2016)

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
por: Golovics, Petra Anna, et al.
Publicado: (2022)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians
por: Hart, Lara, et al.
Publicado: (2020)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
por: Alrajhi, Saad, et al.
Publicado: (2020)

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study
por: Benmassaoud, Amine, et al.
Publicado: (2016)

Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses
por: Strohl, Matthew, et al.
Publicado: (2017)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease
por: Restellini, Sophie, et al.
Publicado: (2017)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome
por: Shengir, Mohamed, et al.
Publicado: (2020)

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history
por: Magrì, Salvatore, et al.
Publicado: (2019)

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
por: Strohl, Matthew, et al.
Publicado: (2018)

The Relationship between Visceral Adiposity and Nonalcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter in People with HIV: A Pilot Study
por: Sebastiani, Giada, et al.
Publicado: (2022)

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
por: Golovics, P, et al.
Publicado: (2022)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease Is a Risk Factor for Thiopurine Hepatotoxicity in Crohn’s Disease
por: George, Alvin T, et al.
Publicado: (2023)

Association between endotoxemia and histological features of nonalcoholic fatty liver disease
por: Kitabatake, Hiroyuki, et al.
Publicado: (2017)

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
por: Weinstein, Ali A, et al.
Publicado: (2022)

Management of inflammatory bowel disease with Clostridium difficile infection
por: D’Aoust, Julie, et al.
Publicado: (2017)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
por: Khoudari, George, et al.
Publicado: (2019)

Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative
por: Pitisuttithum, Panyavee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rqkslnr7m3fq2nqrao1r07i35a